Efficacy and safety evaluation of Ticagrelor in acute coronary syndrome
YANG Rui-feng
Abstract：Objective To observe the efficacy and safety of Ticagrelor in the treatment of acute coronary syndromes.Methods 120 cases of ACS patients diagnosed in our hospital from January 2015 to January 2017 were selected,including acute myocardial infarction and unstable angina pectoris.Stent implantation or balloon dilatation were performed and divided into two groups according to the medication:60 patients in the control group (Clopidogrel) and 60 patients with Ticagrelor.The adverse effects of MACCE and severe bleeding and dyspnea were observed in the two groups during the operation and 6 months after the operation.Results Comparing with pre treated group,the TIMI of either the control group or the Ticagrelor group was significant improved (P＜0.05).The improvement of Ticagrelor group was better than the control group.Both the 6 months of intraoperative or postoperative,Ticagrelor group major adverse cardiovascular and cerebrovascular events including angina pectoris,myocardial infarction and stent thrombosis were significantly lower than that of Clopidogrel group (P＜0.05).And severe bleeding,dyspnea,bradycardia,adverse reactions did not increase significantly,and there was no significant difference between the two (P＞0.05).Conclusion For ACS patients,the combination of TicagTelor and Aspirin therapy significantly reduces the risk of severe cardiovascular events,while severe bleeding and other adverse events have not increased significantly.
Keywords：Acute coronary syndromeTicagrelorClopidogrel
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1026-1029 )